TP53 and pancreatic neoplasm: This functional dichotomy aligned with one recent finding demonstrating RG7388’s efficacy in TP53mutant pancreatic cancer cells [55], and is further substantiated by the preserved NOXA induction in TP53 knockdown models (Supplementary Fig. 3C), confirming mutant p53-independent regulation.